外周血细胞因子在原发性肝癌TACE术后疗效评估中的研究进展  

Progress in research on peripheral blood cytokines for evaluating efficacy after TACE in primary liver cancer

作　　者：王林[1] 杨小莉[1] 晏玉玲 WANG Lin;YANG Xiaoli;YAN Yuling(Department of Gastroenterology and Hepatology,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China)

机构地区：[1]四川大学华西医院消化内科,四川成都610041

出　　处：《中华全科医学》2024年第11期1818-1821,1841,共5页Chinese Journal of General Practice

基　　金：四川省自然科学基金项目(2022YFS03589)。

摘　　要：原发性肝癌是全球范围内发病率、致死率较高的恶性肿瘤之一,及时有效的治疗及精准的疗效评估对于提高患者生存率具有重要意义。经动脉化疗栓塞(TACE)是目前治疗中晚期原发性肝癌的重要方法,其疗效评估的准确性直接影响治疗策略的调整和优化。然而,目前常规的疗效评估方法,如影像学检查和临床表现评估,存在时效性差和敏感性低的局限。近年来,外周血细胞因子在TACE术后的疗效评估中展现出了一定的应用前景。本文详细探讨炎症因子如白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α),免疫调节因子如程序性细胞死亡受体-1(PD-1),血管生成因子如血管内皮生长因子(VEGF)以及细胞生长和分化因子在TACE术后疗效评估中的作用与研究进展。这些因子的水平变化不仅能够作为肿瘤生物学行为和治疗反应的早期标志物,同时还可揭示患者的预后信息。此外,综合分析这些生物标志物的变化可为揭示肿瘤微环境的复杂性和动态变化提供更多信息,增强对肝癌治疗机制的理解。未来需要更加深入地研究这些生物标志物在TACE治疗前后的定量变化、相互作用及其与肿瘤微环境的关系,以期构建一个综合、多层面的疗效评估模型,以更精确地监控疗效,为临床提供决策支持,从而定制个性化的治疗方案,优化治疗结果,最终提高患者的生存率和生活质量。Primary liver cancer ranks among the most prevalent and deadly malignancies globally,making timely and effective treatment,along with precise efficacy assessment,crucial for improving patient survival rates.Transarterial chemoembolization(TACE)is a vital treatment for intermediate and advanced stages of primary liver cancer,and the accuracy of its efficacy assessment directly influences the adjustment and optimization of treatment strategies.However,current conventional assessment methods,such as imaging studies and clinical evaluations,face limitations in terms of timeliness and sensitivity.In recent years,peripheral blood cytokines have emerged as promising indicators for evaluating efficacy assessment following TACE.This review explores the roles and research progress of inflammatory factors,such as interleukin-6(IL-6)and tumor necrosis factor-alpha(TNF-α),immune modulatory factors like programmed cell death receptor-1(PD-1),angiogenic factors such as vascular endothelial growth factor(VEGF),and cell growth and differentiation factors in post-TACE efficacy assessments.Changes in these factors not only serve as early biomarkers of tumor biology and treatment response but also provide valuable prognostic information.Furthermore,a comprehensive analysis of these biomarkers provides deeper insights into the complexities and dynamic changes within the tumor microenvironment,enhancing our understanding of liver cancer treatment mechanisms.Future research should focus on the quantitative changes,interactions,and relationships of these biomarkers before and after TACE treatment.This approach aims to develop a comprehensive,multi-dimensional efficacy assessment model.This model would enable precise monitoring of treatment effectiveness,offer clinical decision-making,and facilitate personalized treatment plans to optimize outcomes,ultimately improve patient survival rates and quality of life.

关 键 词：原发性肝癌 经动脉化疗栓塞 外周血细胞因子 疗效评估 研究进展 

分 类 号：R735.7[医药卫生—肿瘤] R730.5[医药卫生—临床医学]